Abstract
Castration-resistant prostate cancer (CRPC) is characterized by poor prognosis and a median survival ranging from 10 to 20 months. Few therapeutic targets have been identified in CRPC, and further studies are needed to unravel the complex mechanism underlying tumor resistance and spread. Circulating 17²-estradiol levels are elevated as men age, impacting the prostate. Furthermore, estroge…